Prevention of renal osteodystrophy in predialysis patients

American Journal of the Medical Sciences

Volumn 317, Issue 6, 1999, Pages 398-404

  Sanchez, Cheryl P ^a   Goodman, William G ^a   Salusky, Isidro B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcitriol therapy; Predialysis population; Renal failure; Renal osteodystrophy; Secondary hyperparathyroidism

Indexed keywords

ALFACALCIDOL; CALCITRIOL; PHOSPHATE BINDING AGENT; VITAMIN D;

BONE METABOLISM; CALCIUM HOMEOSTASIS; CONFERENCE PAPER; DIALYSIS; DIET RESTRICTION; HIGH RISK POPULATION; HUMAN; KIDNEY FUNCTION; MINERAL METABOLISM; PATHOGENESIS; PROTEIN DEGRADATION; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM;

EID: 0033505903     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9629(15)40553-1     Document Type: Conference Paper

References (59)

1. Cundy T, Hand DJ, Oliver DO, et al. Who gets renal bone disease before beginning dialysis? Br Med J (Clin Res Ed) 1985;290:271-5.
2. Tougaard L, Sørensen E, Brøchner-Mortensen J, et al. Controlled trial of 1α-hydroxycholecalciferol in chronic renal failure. Lancet 1976;1044-7.
3. 3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function. Clin Nephrol 1980;13:103-8.
4. 3 in predialysis renal bone disease. Clin Endocrinol 1977;7(Suppl):109S-116S.
5. Christiansen C, Rødbro P, Christiansen MS, et al. Is 1,25-dihydroxycholecalciferol harmful to renal function in patients with chronic renal failure? Clin Endocrinol 1981;15: 229-36.
6. Llach F, Massry SG, Singer FR, et al. Skeletal resistance of endogenous parathyroid hormone in patients with early renal failure. A possible cause for secondary hyperparathyroidism. J Clin Endocrinol Metab 1975;41:339-45.
7. Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51:328-36.
8. Portale AA, Booth BE, Tsai HC, et al. Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency. Kidney Int 1982;21:627-32.
9. Yamamoto M, Igaroshi T, Miramatsu M, et al. Hypocalcemia increases and hypercalcemia decreases the steady state level of parathyroid hormone messenger ribonucleic acid in the rat. J Clin Invest 1989;83:1053-6.
10. Goldman R, Bassett SH. Phosphorus excretion in renal failure. J Clin Invest 1954;33:1623-30.
11. 3 in the parathyroid glands of patients with renal failure. N Engl J Med 1987;316:1573-7.
12. Dusso A, Lopez-Hilker S, Lewis-Fich J, et al. Metabolic clearance rates and production rate of calcitriol in uremia. Kidney Int 1989;35:860-4.
13. Silver J, Russel J, Sherwood LM. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Nat Acad Sci U S A 1985;82:4270-3.
14. 3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 1986;119:2864-6.
15. Shvil Y, Naveh-Many T, Barach P, et al. Regulation of parathyroid cell gene expression in experimental uremia. J Am Soc Nephrol 1990;1:99-104.
16. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436-43.
17. Reiss E, Canterbury JM, Bercovitz MA, et al. The role of phosphorus in the secretion of parathyroid hormone in man. J Clin Invest 1970;49:2146-52.
18. Fournier AE, Arnaud CD, Johnson WJ, et al. Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. J Clin Invest 1971;50:599-605.
19. Slatopolsky E, Gradowska L, Kashemsant C, et al. The control of phosphorus excretion in uremia. J Clin Invest 1996;45:672-7.
20. Lopez-Hilker S, Galceran T, Chan YL, et al. Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest 1986;78:1097-102.
21. Portale AA, Booth BE, Halloran BP, et al. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984;73:1580-4.
22. Lopez-Hilker S, Dusso AS, Rapp NS, et al. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1990;259:F432-7.
23. Ureña P, Ferreira A, Morieux C, et al. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage in growth plate of uremic rats. Nephrol Dial Transplant 1996; 11:2008-16.
24. Reichel H, Deibert B, Schmidt-Gayk H, et al. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991;6:162-9.
25. Hamdy NAT, Kanis JA, Beneton MNC, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995 Feb 11;310:358-63.
26. Brossard JH, Cloutier M, Roy L, et al. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in interpretation of PTH values. J Clin Endocrinol Metab 1996; 81:3923-9.
27. Malluche HH, Ritz E, Lange HP, et al. Bone histology in incipient and advanced renal failure. Kidney Int 1976;9:355-62.
28. 3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 1989;35:661-9.
29. Eke FU, Winterborn MH. Effect of low dose 1α-hydroxycholecalciferol on glomerular function in moderate renal failure. Arch Dis Child 1983;58:810-3.
30. Coen G, Mazzaferro S, Ballanti P, et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant 1996;11:813-9.
31. 3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone. J Bone Miner Res 1995;10:197-204.
32. Hernandez D, Concepcion MT, Lorenzo V, et al. Adynamic bone disease with negative aluminum staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 1994;9:517-23.
33. Cohen-Solal ME, Sebert JL, Boudailliez B, et al. Non-aluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment? Bone 1992;13:1-5.
34. Salusky IB, Ramirez JA, Oppenheim W, et al. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994;45:253-8.
35. Andress DL, Endres DB, Maloney NA, et al. Comparison of parathyroid hormone assays with bone histomorphometry in renal osteodystrophy. J Clin Endocrinol Metab 1986;63: 1163-9.
36. Coen G, Mazzaferro S, Ballanti P, et al. Two-site immunoradiometric intact PTH assay versus C-terminal PTH in predicting osteodystrophic bone lesions in predialysis chronic renal failure. J Lab Clin Med 1993;122:103-9.
37. Maschio G, Oldrizzi L, Tessitore N, et al. Effects of dietary and protein restriction on the progression of early renal failure. Kidney Int 1982;22:371-6.
38. Blumenkratz MJ, Kopple JD, Moran JK, et al. Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 1982;21:862-7.
39. Alfrey AC, Hegg A, Craswell P. Metabolism and toxicity of aluminum in renal failure. Am J Clin Nutr 1980;33:1509-16.
40. Salusky IB, Coburn JW, Paunier L, et al. Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysis. J Pediatr 1984;105:717-20.
41. Bakir AA, Hryhorczuk DO, Berman E, et al. Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. Trans Am Soc Artif Intern Organs 1986;32:171-6.
42. Schaefer K, Sheer J, Asmus G, et al. The treatment of uremic hyperphosphatemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 1991;6:171-5.
43. Sheikh MS, Maguire JA, Emmett M, et al. Reduction of dietary phosphorus absorption by phosphorus binders: a theoretical, in vitro, and in vivo study. J Clin Invest 1989;83:66-73.
44. Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as an effective phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986;315:157-61.
45. Moriniere P, Roussel A, Tahiri Y, et al. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc 1982;19:784-7.
46. Tsukamoto Y, Moriya R, Nagoba Y, et al. Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure. Am J Kidney Dis 1995;25:879-86.
47. Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997;12:1640-4.
48. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71.
49. Haussler MR, McCain TA. Basic and clinical concepts related to vitamin D metabolism and action. N Eng J Med 1977;297:974-5.
50. Gray R, Boyle I, De Luca HF. Vitamin D metabolism: the role of kidney tissue. Science 1971;172:1232-5.
51. Brickman AS, Coburn JW, Norman AW. Action of 1,25-dihydrocholecalciferol, a potent kidney produced metabolite of vitamin D3 in uremic man. N Engl J Med 1972;287:891-5.
52. Halick MF. Vitamin D and the kidney. Kidney Int 1987;32: 912-29.
53. Healy MD, Malluche HH, Goldstein DA, et al. Effects of long-term therapy with calcitriol in patients with moderate renal failure. Arch Intern Med 1980;140:1030-3.
54. Bianchi ML, Colantonio G, Campanini F, et al. Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 1994;9:1595-9.
55. Ritz E, Kuster S, Schmidt-Gayk H, et al. Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphorus in patients with moderate renal failure. Nephrol Dial Transplant 1995;10:2228-34.
56. 3 in childhood renal osteodystrophy. N Engl J Med 1978;298:238-42.
57. Chan JCM, McEnery PT, Chinchilli VM, et al. A prospective, double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol. J Pediatr 1994;124: 520-8.
58. Nordal KP, Dahl E, Halse J, et al. Long-term low-dose calcitriol treatment in predialysis chronic renal failure: can it prevent hyperparathyroid bone disease? Nephrol Dial Transplant 1995;10:203-6.
59. 3: humoral and histomorphometric results. Miner Electrolyte Metab 1986; 12:375-82